Abstract
In a double-blind, prospective study, 40 patients diagnosed with DSM-IV generalized anxiety disorder and stabilized on alprazolam therapy were randomized to receive the same dose of either conventional or sustained-released alprazolam for two weeks, followed by the other formulation of alprazolam in an identical dose for a further two weeks. Conventional alprazolam was administered thrice daily while the sustained-release formulation was administered once-daily, in the morning. Thirty four patients completed the study. Recruitment into the study was associated with a significant decrease in all measures of illness severity; however, no efficacy differences between the two forms of alprazolam were observed. Adverse effects, specifically insomnia, were reported more with the sustained-release formulation. It is concluded that once-daily sustained-release alprazolam is as effective as the conventional form of the drug, and may be preferable because of a wide range of advantages; in this study, the higher incidence of adverse effects with the sustained-release drug was probably an artefact of the experimental design, which fostered a (nighttime) state of partial drug withdrawal.
Keywords: Alprazolam, sustained-release alprazolam, generalized anxiety disorder, drug trial
Full Text
The Full Text of this article is available as a PDF (251.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Levine J., Schooler N. R. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22(2):343–381. [PubMed] [Google Scholar]
- Londborg P. D., Wolkow R., Smith W. T., DuBoff E., England D., Ferguson J., Rosenthal M., Weise C. Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry. 1998 Jul;173:54–60. doi: 10.1192/bjp.173.1.54. [DOI] [PubMed] [Google Scholar]
- Pecknold J. C. Discontinuation reactions to alprazolam in panic disorder. J Psychiatr Res. 1993;27 (Suppl 1):155–170. doi: 10.1016/0022-3956(93)90025-w. [DOI] [PubMed] [Google Scholar]
- Pecknold J., Luthe L., Munjack D., Alexander P. A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder. J Clin Psychopharmacol. 1994 Oct;14(5):314–321. [PubMed] [Google Scholar]
- Schweizer E., Patterson W., Rickels K., Rosenthal M. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry. 1993 Aug;150(8):1210–1215. doi: 10.1176/ajp.150.8.1210. [DOI] [PubMed] [Google Scholar]
- Weiss M., Gaston L., Propst A., Wisebord S., Zicherman V. The role of the alliance in the pharmacologic treatment of depression. J Clin Psychiatry. 1997 May;58(5):196–204. doi: 10.4088/jcp.v58n0504. [DOI] [PubMed] [Google Scholar]